BLUE bluebird bio
- 0.606
- +0.032+5.54%
- 0.601
- -0.005-0.78%
bluebird bio News
bluebird bio | 10-Q: Q1 2024 Earnings Report
Express News | Bluebird bio Inc -Restatement Had No Impact on Company's Cash Position or Revenue
Bluebird Bio Announces Completion Of Its Restatement And Filing Of Its 2023 Form 10-K And Q1 2024 Form 10-Q >BLUE
bluebird bio | 10-K: FY2023 Annual Report
California Launches $500 Million Initiative for Zero-Emission School Buses -- OPIS
FDA Will Not Meet Ahead of Bluebird Bio's Sickle Cell Disease Gene Therapy PDUFA Date
Bluebird Bio Announces September Investor Events
Bluebird Bio Works to Resolve Financial Reporting Delays
Express News | Bluebird bio Announces Receipt of Expected Notices From Nasdaq
Bluebird Bio Announces Receipt of Expected Notices From Nasdaq
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
What 4 Analyst Ratings Have To Say About Bluebird Bio
Bluebird Bio Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Multiple Firms Lowered Their Respective Price Targets on the Stock.
RBC Capital Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $4
Bluebird Bio Price Target Maintained With a $4.00/Share by RBC Capital
Bluebird Bio Is Maintained at Overweight by Barclays
BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $3
A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $3 to $4
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysis
Price Target
No Data
No Data
